Podoplanin is a useful marker for identifying mesothelioma in malignant effusions

Diagnostic Cytopathology

Volumn 38, Issue 4, 2010, Pages 264-269

  Hanna, Atef ^a   Pang, Yijun ^a   Bedrossian, Carlos W M ^b   Dejmek, Annika ^c   Michael, Claire W ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Malignant effusion; Mesothelioma; Podoplanin

Indexed keywords

CALRETININ; PODOPLANIN; WT1 PROTEIN;

ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL; CANCER CYTODIAGNOSIS; CELL COUNT; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG ADENOCARCINOMA; MALIGNANT MESOTHELIOMA; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; PLEURAL EFFUSION, MALIGNANT; TUMOR MARKERS, BIOLOGICAL;

EID: 77949419467     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.21340     Document Type: Article

References (41)

1. Price B. Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol 1997;145:211-218.
2. Spirtas R, Heineman EF, Bernstein L, et al. Malignant mesothelioma: attributable risk of asbestos exposure. Occup Environ Med 1994;51:804-811.
3. Butnor KJ. My approach to the diagnosis of mesothelial lesions. J Clin Pathol 2006;59:564-574.
4. Ordonez NG. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: A comparative study. Mod Pathol 2006;19:34-48.
5. Ordonez NG. What are the current best Immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update Hum Pathol 2007;38:1-16.
6. Schacht V, Dadras S, Johnson L, Jackson D, Hong Y, Detmar M. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 2005;166:913-921.
7. Chu AY, Litzky LA, Pasha TL, Acs G, Zhang PJ. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol 2005;18:105-110.
8. Kimura N, Kimura I. Podoplanin as a marker for mesothelioma. Pathol Int 2005;55:83-86.
9. Ordonez NG. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol 2005;36:372-380.
10. Breiteneder-Geleff S, Soleiman A, Kowalski H, et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: Podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 1999;154:385-394.
11. Wetterwald A, Hofstetter W, Cecchini MG, et al. Characterization and cloning of the E11 antigen, a marker expressed by rat osteoblasts and osteocytes. Bone 1996;18:125-132.
12. Breiteneder-Geleff S, Matsui K, Soleiman A, et al. Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is downregulated in puromycin nephrosis. Am J Pathol 1997;151:1141-1152.
13. Xie Q, Chen L, Fu K, et al. Podoplanin (d2-40): A new immuno-histochemical marker for reactive follicular dendritic cells and follicular dendritic cell sarcomas. Int J Clin Exp Pathol 2008;1:276-284.
14. Kalof AN, Cooper K. D2-40 immunohistochemistry-so far! Adv Anat Pathol 2009;16:62-64.
15. Marchevsky AM. Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch Pathol Lab Med 2008;132:397-401.
16. Atsumi N, Ishii G, Kojima M, Sanada M, Fujii S, Ochiai A. Podoplanin, a novel marker of tumor-initiating cells in human squamous cell carcinoma A431. Biochem Biophys Res Commun 2008;373:36-41.
17. Raica M, Cimpean AM, Ribatti D. The role of podoplanin in tumor progression and metastasis. Anticancer Res 2008;28:2997-3006.
18. Padgett DM, Cathro HP, Wick MR, Mills SE. Podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin. Am J Surg Pathol 2008;32:123-127.
19. Doglioni C, Dei Tos AP, Laurino L, et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol 1996;20:1037-1046.
20. Gotzos V, Vogt P, Celio MR. The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type. Pathol Res Pract 1996;192:137-147.
21. Ordonez NG. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. Mod Pathol 1998;11:929-933.
22. Barberis MCP, Faleri M, Veronese S, Casadio C, Viale G. Calretinin: A selective marker of normal and neoplastic mesothelial cells in serous effusions. Acta Cytol 1997;41:1757-1761.
23. Clover J, Oates J, Edwards C. Anti-cytokeratin 5/6: A positive marker for epithelioid mesothelioma. Histopathology 1997;31:140-143.
24. Ordonez NG. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am J Surg Pathol 1998;22:1215-1221.
25. Cury PM, Butcher DN, Fisher C, Corrin B, Nicholson AG. Value of the mesotheliumassociated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Mod Pathol 2000;13:107-112.
26. Amin KM, Litzky LA, Smythe WR, et al. Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol 1995;146:344-356.
27. Kumar-Singh S, Segers K, Rodeck U, et al. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis. J Pathol 1997;181:67-74.
28. Oates J, Edwards C. HBME-1. MOC-31, WT1 and calretinin: As assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology 2000;36:341-347.
29. Walker C, Rutten F, Yuan X, Pass H, Mew DM, Everitt J. Wilms' tumor suppressor gene expression in rat and human mesothelioma. Cancer Res 1994;54:3101-3106.
30. Ruitenbeek T, Gouw ASH, Poppema S. Immunocytology of body cavity fluids. MOC-31, a monoclonal antibody discriminating current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma 13 between mesothelial and epithelial cells. Arch Pathol Lab Med 1994;118:265-269.
31. Edwards C, Oates J. OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: An assessment of their use in formalin-fixed and paraffin wax embedded material. J Clin Pathol 1995;48:626-630.
32. Sosolik RC, McGaughy VR, De Young BR. Anti-MOC-31: A potential addition to the pulmonary adenocarcinoma versus mesothelioma immunohistochemistry panel. Mod Pathol 1997;10:716-719.
33. Ordonez NG. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. Hum Pathol 1998;29:166-169.
34. Moch H, Oberholzer M, Dalquen P, Wegmann W, Gudat F. Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue. I. Immunohistochemical findings. Virchows Arch Pathol A Pathol Anat 1993;423:19-27.
35. Bailey ME, Brown RW, Mody DR, Cagle P, Ramzy I. Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions: Comparison with carcinoembryonic antigen, B72.3 and Leu-M1. Acta Cytol 1996;40:1212-1216.
36. Ordonez NG. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature. Am J Clin Pathol 1998;109:85-89.
37. Warnock ML, Stoloff A, Thor A. Differentiation of adenocarcinoma of the lung from mesothelioma. Periodic acid-Schiff, monoclonal antibodies B72.3, and Leu M1. Am J Pathol 1988;133:30-38.
38. Garcia-Prats MD, Ballestin C, Sotelo T, Lopez-Encuentra A, Mayordomo JI. A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours. Histopathology 1998;32:462-472.
39. Sheibani K, Battifora H, Burke JS. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas: An immunohistologic analysis demonstrating the value of Leu M1 antigen. Am J Pathol 1986;123:212-219.
40. Müller AM, Franke FE, Müller KM. D2-40: A reliable marker in the diagnosis of pleural mesothelioma. Pathobiology 2006;73:50-54.
41. Hinterberger M, Reineke T, Storz M, Weder W, Vogt P, Moch H. D2-40 and calretinin: A tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation. Mod Pathol 2007;20:248-255.